circRNA basic information
circBase ID: hsa_circ_0081143
Name: hsa_circ_COL1A2
Synonym: circ_0081143
Host Gene: COL1A2
Genomic location(hg19): chr7:94044537-94055169:+
Genomic location(hg38): chr7:94415225-94425857:+
Subcellular localization: not tested
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
0001056
MONDO name: gastric cancer
Disease details: gastric cancer / GC
Disease DO ID:
10534
Disease MeSH ID:
-
Disease NCIt ID:
C9331
Disease ICD11 ID:
1397617262
Disease OMIM ID:
613659
Species: Human
Species details: Homo sapiens
Tissue specimen:

GC tumor tissues; adjacent normal tissues

Cell lines:

GES1; HGC-27; AGS; HGC-27/DR; AGS/DR

In vivo animal model:

cell line-derived xenograft

circRNA-disease information
Expression pattern:
UP
Associated gene: YES1
Associated microRNA: miR-129-2-3p
Biological function: promotes doxorubicin resistance and malignant phenotypes (proliferation, migration, invasion) and inhibits apoptosis in gastric cancer
Molecular mechanism: ceRNA mechanism: circ_0081143 sponges miR-129-2-3p to increase YES1 expression
Biological pathway or process:

chemoresistance (promotes); proliferation (promotes); apoptosis (inhibits); migration (promotes); invasion (promotes); ceRNA regulation (promotes)

Detected method:
Q
Validation methods:

RT-qPCR; Clinical Sample Validation; Transfection; MTT; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; Luciferase Reporter Assay; RNA Pull-Down; In Vivo Animal Model

Clinical significance:

circ_0081143 is a promising/prospective target for treatment of GC with doxorubicin resistance

Description:

circ_0081143 (from COL1A2) is up-regulated in gastric cancer, especially doxorubicin-resistant tumors and cells, and promotes malignant behaviors and doxorubicin resistance. Mechanistically, it sponges miR-129-2-3p to derepress YES1 (miR-129-2-3p/YES1 axis). Inhibiting circ_0081143 sensitizes cells to doxorubicin and suppresses xenograft tumor growth.

Confidence score:

0.6825

Other information
Title:

Circ_0081143 Contributes to Gastric Cancer Malignant Development and Doxorubicin Resistance by Elevating the Expression of YES1 by Targeting mziR-129-2-3p.

Journal: Gut and liver
Published: 2022
PubMed ID: 35686503
Study type:

combined biological and clinical study

Data availability: Supplementary materials can be accessed at https://doi.org/10.5009/gnl210354.
Code availability: -